Synthesis of novel benzo[b]furans and benzo[b]thiophenes 243
J=1.7, Ar), 6.47 (1 H, t, J=1.7, Ar), 3.77 (3 H, s, OMe), 3.71 (6 H,
s, 2×OMe). 13C NMR (CDCl3) δ 161.2, 159.5, 141.1, 139.7, 138.7,
137.9, 132.4, 130.9, 126.8, 124.7, 124.5, 123.4, 122.2, 114.1, 108.6,
105.8, 100.0, 55.6.
Hsieh, H. P.; Liou, J. P.; Mahindroo, N. Pharmaceutical design of
antimitotic agents based on combretastatins. Curr. Pharm. Des.
2005, 11, 1655–1677.
Hu, L.; Li, Z. R.; Li, Y.; Qu, J.; Ling, Y. H.; Jiang, J. D.; Boykin,
D. W. Synthesis and structure-activity relationships of carbazole
sulfonamides as a novel class of antimitotic agents against solid
tumors. J. Med. Chem. 2006, 49, 6273–6282.
Hung, N. T.; Hussain, M.; Malik, I.; Villinger, A.; Langer, P. Site-
selective suzuki cross-coupling reactions of 2,3-dibromobenzo-
furan. Tetrahedron Lett. 2010, 51, 2420–2422.
Hussain, M.; Malik, I.; Villinger, A.; Langer, P. Efficient synthesis
of functionalized 2,3-di(alkenyl)benzothiophenes and dibenzo-
thiophenes based on the first heck reactions of 2,3-di- and 2,3,6-
tribromobenzothiophene. Synlett 2009a, 2691–2695.
Hussain, M.; Nguyen, H. T.; Langer, P. Efficient synthesis of
functionalized dibenzofurans by domino ‘twofold heck/6π-
electrocyclization’ reactions of 2,3-di- and 2,3,5-tribromobenzo-
furan. Tetrahedron Lett. 2009b, 50, 3929–3932.
Lee, L.; Robb, L. M.; Lee, M.; Davis, R.; Mackay, H.; Chavda, S.;
Babu, B.; O’Brien, E. L.; Risinger, A. L.; Mooberry, S. L.; et
al. Design, synthesis, and biological evaluations of 2,5-diaryl-
2,3-dihydro-1,3,4-oxadiazoline analogs of combretastatin-a4. J.
Med. Chem. 2010, 53, 325–334.
Liu, Z.-Y.; Li, Z.-R.; Jiang, L.-D.; Boykin, D. W. Synthesis of novel
4-(diarylmethylene)piperidines. Heterocycl. Commun. 2009, 15,
401–409.
Lorion, M.; Agouridas, V.; Couture, A.; Deniau, E.; Grandclaudon,
P. Syhnthesis and cytotoxic evaluation of cis-locked and con-
strained analogues of combretastatin and combretastatin A4.
Tetrahedron Lett. 2010, 51, 5146–5149.
1
10b; H NMR (acetone-d6) δ 8.62 (1 H, s, OH), 8.34 (2 H, s, OH),
7.91 (1 H, d, J=9.1, Ar), 7.57 (1 H, d, J=9.1, Ar), 7.37–7.32 (2 H, m,
Ar), 7.26 (2 H, d, J=8.4, Ar), 6.79 (2 H, d, J=8.4, Ar), 6.39 (1 H, d,
J=2.1, Ar), 6.31 (2 H, d, J=2.1, Ar). 13C NMR (acetone-d6) δ 159.1,
157.7, 141.4, 139.3, 138.4, 137.8, 132.3, 130.7, 125.6, 124.6, 124.5,
123.2, 122.1, 115.6, 108.9, 102.2; m/z (ESI): 333 (100%, M-H+), 667
(70%, 2M-H+); HRMS: m/z [M-H]+ calc. for C20H13O3S: 333.0591,
found: 333.0586.
Acknowledgements
This research was funded by the Center for Drug Design, the
Academic Health Center, University of Minnesota, MS, USA.
References
Baur, J. A.; Sinclair, D. A. Therapeutic potential of resveratrol:
the in vivo evidence. Nat. Rev. Drug Discov. 2006, 5, 493–506.
Biersack, B.; Effenberger, K.; Knauer, S.; Ocker, M.; Schobert, R.
Ru(eta6-arene) complexes of combretastatin-analogous oxazoles
with enhanced anti-tumoral impact. Eur. J. Med. Chem. 2010a,
45, 4890–4896.
Biersack, B.; Effenberger, K.; Schobert, R.; Ocker, M. Oxazole-
bridged combretastatin A analogues with improved anticancer
properties. Chem. Med. Chem. 2010b, 5, 420–427.
Brachet, E.; Hamze, A.; Peyrat, J. F.; Brion, J. D.; Alami, M.
Pd-catalyzed reaction of sterically hindered hydrazones with aryl
halides: synthesis of tetra-substituted olefins related to iso-com-
bretastatin A4. Org. Lett. 2010, 12, 4042–4045.
Macarulla, M. T.; Alberdi, G.; Gomez, S.; Tueros, I.; Bald, C.;
Rodriguez, V. M.; Martinez, J. A.; Portillo, M. P. Effects of dif-
ferent doses of resveratrol on body fat and serum parameters
in rats fed a hypercaloric diet. J. Physiol. Biochem. 2009, 65,
369–376.
Odlo, K.; Hentzen, J.; dit Chabert, J. F.; Ducki, S.; Gani, O. A.; Sylte,
I.; Skrede, M.; Florenes, V. A.; Hansen, T. V. 1,5-Disubstituted
1,2,3-triazoles as cis-restricted analogues of combretastatin
A-4: synthesis, molecular modeling and evaluation as cytotoxic
agents and inhibitors of tubulin. Bioorg. Med. Chem. 2008, 16,
4829–4838.
Odlo, K.; Fournier-Dit-Chabert, J.; Ducki, S.; Gani, O. A.; Sylte, I.;
Hansen, T. V. 1,2,3-Triazole analogs of combretastatin A-4 as
potential microtubule-binding agents. Bioorg. Med. Chem. 2010,
18, 6874–6885.
Chen, J.; Wang, Z.; Li, C. M.; Lu, Y.; Vaddady, P. K.; Meibohm, B.;
Dalton, J. T.; Miller, D. D.; Li, W. Discovery of novel 2-aryl-
4-benzoyl-imidazoles targeting the colchicines binding site in
tubulin as potential anticancer agents. J. Med. Chem. 2010, 53,
7414–7427.
Cirla, A.; Mann, J. Combretastatins: from natural products to drug
discovery. Nat. Prod. Rep. 2003, 20, 558–564.
Clouser, C. L.; Patterson, S. E.; Mansky, L. M. Exploiting drug repo-
sitioning for discovery of a novel HIV combination therapy. J.
Virol. 2010, 84, 9301–9309.
Roberti, M.; Pizzirani, D.; Recanatini, M.; Simoni, D.; Grimaudo,
S.; Di Cristina, A.; Abbadessa, V.; Gebbia, N.; Tolomeo, M.
Identification of a terphenyl derivative that blocks the cell cycle
in the g0-g1 phase and induces differentiation in leukemia cells.
J. Med. Chem. 2006, 49, 3012–3018.
Schobert, R.; Biersack, B.; Dietrich, A.; Knauer, S.; Zoldakova, M.;
Fruehauf, A.; Mueller, T. Pt(ii) complexes of a combretastatin
A-4 analogous chalcone: effects of conjugation on cytotoxicity,
tumor specificity, and long-term tumor growth suppression. J.
Med. Chem. 2009, 52, 241–246.
Ducki, S.; Mackenzie, G.; Greedy, B.; Armitage, S.; Chabert,
J. F.; Bennett, E.; Nettles, J.; Snyder, J. P.; Lawrence, N. J.
Combretastatin-like chalcones as inhibitors of microtubule
polymerisation. Part 2: structure-based discovery of alpha-aryl
chalcones. Bioorg. Med. Chem. 2009a, 17, 7711–7722.
Ducki, S.; Rennison, D.; Woo, M.; Kendall, A.; Chabert, J. F.;
McGown, A. T.; Lawrence, N. J. Combretastatin-like chalcones
as inhibitors of microtubule polymerization. Part 1: synthesis
and biological evaluation of antivascular activity. Bioorg. Med.
Chem. 2009b, 17, 7698–7710.
Schobert, R.; Biersack, B.; Dietrich, A.; Effenberger, K.; Knauer, S.;
Mueller, T. 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-arylox-
azoles and -n-methylimidazoles that are cytotoxic against com-
bretastatin A resistant tumor cells and vascular disrupting in a
cisplatin resistant germ cell tumor model. J. Med. Chem. 2010,
53, 6595–6602.
Fontecave, M.; Lepoivre, M.; Elleingand, E.; Gerez, C.; Guittet, O.
Resveratrol, a remarkable inhibitor of ribonucleotide reductase.
FEBS Lett. 1998, 421, 277–279.
Fulda, S. Resveratrol and derivatives for the prevention and treat-
ment of cancer. Drug Discov. Today 2010, 15, 757–765.
Heynderickx, A.; Samat, A.; Guglielmetti, R. A one-pot synthesis
of hindered 2,3-diarylbenzo[b]thiophenes via Suzuki reaction.
Synthesis 2002, 213–216.
Siemann, D. W.; Chaplin, D. J.; Walicke, P. A. A review and
update of the current status of the vasculature-disabling agent
Brought to you by | Purdue University Libraries
Authenticated
Download Date | 5/19/15 11:47 AM